NantKwest

What is NantKwest?

NantKwest, operating under the banner of ImmunityBio, stands as a dynamic biotechnology entity with a focus on developing immunotherapeutic agents for a wide range of clinical conditions in the United States. The company prides itself on its innovative product candidates, including activated natural killer (NK) cell therapies aimed at the treatment of virally-induced cancers such as human papilloma virus (HPV) induced cervical and head and neck cancers.

These candidates also target severe viral, fungal, and bacterial infections.

NantKwest's innovative approach includes a Phase II clinical trial for the treatment of polyoma virus-induced Merkel cell carcinoma.

ImmunityBio, a member of the NantWorks ecosystem, seeks to transform cancer treatment by focusing on immune system enhancement rather than solely targeting the disease. Under the leadership of Dr. Patrick Soon-Shiong, the company is invested in creating targeted personalized immunotherapies that strengthen the immune system, employing both innate and adaptive immune responses.

Their investigational cancer therapies and vaccines address the full spectrum of the immune system, activating important components such as NK cells, T cells, macrophages, and establishing immune memory through dendritic cells. ImmunityBio believes this comprehensive approach surpasses the potential of CAR-T therapies or checkpoint inhibitors alone.

With a robust clinical pipeline, the company is also developing potential cancer vaccines and immuno- and cell therapies, which promise to significantly reduce or eliminate the need for conventional high-dose chemotherapy.

Their investigative efforts extend to viral therapies, with breakthrough findings in HIV-infected patients showing that their immune enhancer ANKTIVA can expose HIV-infected cells for recognition and destruction. This opens the possibility for a cure and freedom from life-long antiviral therapy for HIV patients.

Additional endeavors include an HPV vaccine designed to eradicate infection and mitigate the risk of HPV-associated cancers. An abiding commitment to innovation and improving patient outcomes propels ImmunityBio's research and development initiatives, which is well-reflected in their diverse treatment pipelines and clinical trials across multiple tumor types and conditions.